Possible mechanism underlying the effect of Semax on the formation of indomethacin-induced ulcers in rats.
Zhuikova. S E SE; Sergeev. V I VI; Samonina. G E GE; Myasoedov. N F NF
Key Findings
- Semax (50 mg/kg, intraperitoneal) reduced indomethacin‑induced gastric ulcers in rats
- Semax prevented the indomethacin‑induced decrease in gastric wall blood flow
- Semax did not affect baseline gastric blood flow in control rats
Practical Outcomes
- Semax may have gastro‑protective properties by preserving stomach blood flow, but the study used a very high dose and an injection route not typical for humans. For biohackers, the result is interesting but not ready to be turned into a safe, real‑world protocol for ulcer prevention or NSAID use.
Summary
In a rat study, giving a high dose of the peptide Semax protected the stomach from ulcers caused by the NSAID indomethacin, likely by keeping blood flow in the stomach wall stable. The peptide didn’t change normal stomach blood flow but stopped the drop that indomethacin normally causes.
Abstract
Intraperitoneal injection of Semax (synthetic analogue of ACTH4-7, MEHFPGP) in a dose of 50 mg/kg produced a protective effect on rats with experimental indomethacin-induced ulcers. Experiments on narcotized rats showed that Semax in the studied dose had no effect on basal blood flow in the stomach, but prevented reduction of blood flow induced by indomethacin. The antiulcer effect of Semax is probably related to improvement of blood flow in the gastric wall disturbed by indomethacin.
Study Information
pubmed
2002
10.1023/a:1020285909696